Sawgrass Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-2,573
Closed -$473K 187
2021
Q2
$473K Sell
2,573
-65,522
-96% -$11.2M 0.04% 116
2021
Q1
$10.4M Sell
68,095
-11,797
-15% -$1.82M 0.84% 44
2020
Q4
$12.5M Buy
+79,892
New +$10.3M 0.93% 38

Other funds holding ALXN

Sawgrass Asset Management's ALXN Position: Q3 2021 in Review

Sawgrass Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,573 shares — an estimated $473K sold.

Sawgrass Asset Management first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $12.5M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Sawgrass Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sawgrass Asset Management sold 2,573 Alexion Pharmaceuticals shares in Q3 2021, an estimated $473K.
  • Sawgrass Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Sawgrass Asset Management's Alexion Pharmaceuticals position peaked at $12.5M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Sawgrass Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.